Temasek Life Sciences Accelerator

Temasek Life Sciences Accelerator was established as a wholly owned platform of Temasek Holdings, Singapore's sovereign-backed investment company. It functions as a specialized venture builder rather than a conventional fund, receiving its capital and strategic mandate directly from Temasek. This structure gives it a patient-capital posture that distinguishes it from independent life science VCs, which typically operate with fixed fund lives and LP-driven timelines.

TLA sources its deal flow primarily through Singapore's Agency for Science, Technology and Research (A*STAR) and the broader public research university system. The firm evaluates inventions and research programs with commercial potential, then works with the originating scientists to form companies around the intellectual property. This captive sourcing model, built on exclusive or preferential access to A*STAR's research pipeline, gives TLA a proprietary deal channel that external VCs cannot replicate.

TLA targets the pre-seed and seed stages, specifically the gap between laboratory validation and a startup's first institutional venture round. The firm typically enters before a startup has a full management team or commercial product, providing the initial capital and operational infrastructure required to reach Series A readiness. TLA does not lead growth-stage rounds, focusing instead on formation and early de-risking.

TLA's portfolio companies often raise follow-on funding from external VCs, and the firm's incubation model is designed to prepare startups for syndicated Series A rounds. While TLA itself remains a Temasek-backed entity and does not operate as an open fund, its startups benefit from introductions to global life science investors through the Temasek network. Co-investment at the institutional level is not part of TLA's mandate; its role is as company builder and seed investor.

TLA focuses on three main verticals: human health and therapeutics, including diagnostics and medical devices; agri-food technology, such as alternative proteins and sustainable agriculture; and industrial biotechnology. The firm does not invest in health-tech software plays or digital health apps without a core biological or chemical innovation. Its investment threshold requires a defensible scientific moat, typically in the form of patent-protected research from A*STAR or a Singapore university.